文献速递艾滋病与性传播感染

HIV感染者换用多替拉韦加拉米夫定与继续三联方案相比的血端粒长度增益:一项纵向、前瞻性、匹配、对照研究

Blood telomere length gain in people living with HIV switching to dolutegravir plus lamivudine versus continuing triple regimen: a longitudinal, prospective, matched, controlled study.
PubMed 文献 · J Antimicrob Chemother · 2023-01-01

该纵向前瞻性匹配对照研究纳入120例病毒学抑制的HIV成人,1:1匹配后比较换用多替拉韦加拉米夫定双药治疗与继续三联方案对血端粒长度的影响。48周时双药组血端粒长度均值显著增加(P=0.003),三联组无显著变化(P=0.656)。作者认为简化至多替拉韦加拉米夫定可能对血端粒长度有正向影响。

要点

  • 48周时双药组血端粒长度均值显著增加(P=0.003),三联组无显著变化(P=0.656)。
  • 总体血端粒长度均值增加+0.161(95%CI 0.054-0.268)(P=0.004)。
  • 基线时两组血端粒长度均值可比(P=0.973),48周病毒免疫学状态稳定。

核心结论

  • 在病毒学抑制的HIV感染者中,简化至多替拉韦加拉米夫定在1年随访后与继续三联治疗相比,血端粒长度增益更高。
  • 作者认为作为简化策略,多替拉韦加拉米夫定可能对血端粒长度有正向影响。

研究设计与样本

  • 纵向、前瞻性、匹配、对照研究,纳入120例病毒学抑制且接受稳定三药ART的成人,双药组与三联组各60例,按年龄、性别、HIV诊断年数、ART年数及锚定药物1:1匹配。
  • 双药组在基线换用多替拉韦加拉米夫定,三联组继续含两个NRTI骨干加锚定药物的标准三联治疗。
  • 采用单色多重qPCR在基线和48周评估血端粒长度。

主要发现

  • 基线时两组血端粒长度均值可比(P=0.973)。
  • 48周时病毒免疫学状态稳定,总体血端粒长度均值增加+0.161(95%CI 0.054-0.268)(P=0.004)。
  • 组内分析显示双药组血端粒长度均值显著增加(P=0.003),三联组无显著变化(P=0.656)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Blood telomere length (BTL) is a validated biomarker of aging. ART reduces immunosenescence and has benefits in terms of BTL in people living with HIV (PLWH). However, it has also been observed that ART containing NRTIs, such as tenofovir or abacavir, which are potent inhibitors of human telomerase activity in vitro, might negatively affect BTL. Here we investigated the effects on BTL 1 year after switching to a dual therapy (DT) with dolutegravir + lamivudine versus maintaining a standard triple therapy (TT) with a two-NRTI backbone and an anchor drug. METHODS: This was a longitudinal, prospective, matched, controlled study that included virologically suppressed adults on stable three-drug ART who either switched at baseline (BL) to DT or maintained TT. The DT and TT groups were 1:1 matched for age, sex, years since HIV diagnosis, years on ART and anchor drug. BTL was assessed by a monochrome multiplex qPCR at BL and after 48 weeks (W48). RESULTS: We enrolled 120 PLWH, i.e. 60 participants in each group. At BL, the BTL means were comparable between the two groups (P = 0.973). At W48, viro-immunological status was stable and an overall increase in the mean BTL was observed, i.e., +0.161 (95%CI, 0.054-0.268) (P = 0.004). However, the within-group analysis showed a significant mean BTL gain in the DT group (P = 0.003) but not in the TT group (P = 0.656). CONCLUSIONS: In this setting of virologically suppressed PLWH, simplifying to dolutegravir + lamivudine was associated with a higher gain in BTL than maintaining triple therapy after the 1 year follow-up. These findings suggest that as a simplification strategy dolutegravir + lamivudine might have a positive effect on BTL.

来源:J Antimicrob Chemother,查看原文。版权归原作者所有。

引用

  1. Lombardi F, Sanfilippo A, Fabbiani M, et al. Blood telomere length gain in people living with HIV switching to dolutegravir plus lamivudine versus continuing triple regimen: a longitudinal, prospective, matched, controlled study. J Antimicrob Chemother. 2023. PMID: 37534393. doi:10.1093/jac/dkad237

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。